Biotech entity
pharma is the sole category represented across all 1 tracked stories. Agilent is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Adam Alanoff appears in 1 tracked Biotech story from February 26, 2026. The tracked stories average 2 original sources each.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Agilent is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Adam Alanoff appears in 1 tracked Biotech story from February 26, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Adam Alanoff. Shared-story counts are live from our verified record — not editorial picks.
Agilent reported a 4.4% core revenue growth in Q1 2026, driven by a strong 7% uptick in the pharmaceutical sector despite an 8% decline in academic and government markets. The company is navigating margin pressures from new tariffs while leaning into high-growth areas like GLP-1 manufacturing and CDMO services.
Adam Alanoff is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
